ISRCTN50212645已完成未知
A Phase III prospective, interventional, cohort, superiority study to evaluate the benefit of rapid COVID-19 genomic sequencing (the COVID-19 GENOMICS UK Project) on infection control in preventing the spread of the virus in UK NHS hospitals
niversity College London0 个研究点目标入组 2,170 人开始时间: 2020年5月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 2,170
研究概览
简要总结
2022 Protocol article in http://dx.doi.org/10.1136/bmjopen-2021-052514 (added 12/08/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36098502/ (added 27/09/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 14/04/2021:
- •1. Participants must have confirmed COVID-19 infection and be a hospital-onset COVID-19 infection (HOCI)
- •2. Participants must have provided nasal swab/pharyngeal swab/combined nasal and pharyngeal swab/nasopharyngeal aspirate or bronchoalveolar lavage sample for evaluation in the COG-UK project.
- •3. Participants may be of any age or gender to be included in the study. For clarity, in the above criterion a potential HOCI is an admitted patient at site with first confirmed test for COVID-19 >48 h after admission, where they were not suspected to have COVID-19 at time of admission
- •Previous inclusion criteria:
- •1. Participants must have confirmed COVID-19 infection and either:
- •1.1. Be a potential hospital-onset COVID-19 infection (HOCI), or
- •1.2. Potential workplace infection with SARS CoV-2 for site-based healthcare workers
- •2. Participants must have provided nasal swab/pharyngeal swab/combined nasal and pharyngeal swab/nasopharyngeal aspirate or bronchoalveolar lavage sample for evaluation in the COG-UK project.
- •3. Participants may be of any age or gender to be included in the study. For clarity, in the above criterion a potential HOCI is an admitted patient at site with first confirmed test for COVID-19 >48 h after admission, where they were not suspected to have COVID-19 at time of admission
排除标准
- •Does not meet inclusion criteria
研究者
相似试验
进行中（未招募）
1 期
A three-year study to explore the long-term evolution of sign and symptoms of severe Dry Eye Disease in patients receiving IKERVIS® (1mg/ml ciclosporin) eye drops.DRY EYE DISEASE WITH SEVERE KERATITISMedDRA version: 20.0Level: PTClassification code 10023332Term: KeratitisSystem Organ Class: 10015919 - Eye disordersEUCTR2017-002660-41-PLSANTEN SAS350
进行中（未招募）
1 期
A three-year study to explore the long-term evolution of sign and symptoms of severe Dry Eye Disease in patients receiving IKERVIS® (1mg/ml ciclosporin) eye drops.DRY EYE DISEASE WITH SEVERE KERATITISMedDRA version: 20.0Level: PTClassification code 10023332Term: KeratitisSystem Organ Class: 10015919 - Eye disordersEUCTR2017-002660-41-ITSANTEN SAS350
进行中（未招募）
1 期
A three-year study to explore the long-term evolution of sign and symptoms of severe Dry Eye Disease in patients receiving IKERVIS® (1mg/ml ciclosporin) eye drops.DRY EYE DISEASE WITH SEVERE KERATITISMedDRA version: 20.0Level: PTClassification code 10023332Term: KeratitisSystem Organ Class: 10015919 - Eye disordersEUCTR2017-002660-41-CZSANTEN SAS350
进行中（未招募）
不适用
ASSESS-meso: a long-term study looking at people with mesothelioma (cancer of the outer lining of the lung) that will gather information on symptoms, disease processes and factors that affect survivalMesothelioma (cancer of the outer lining of the lung)CancerISRCTN61861764orth Bristol NHS Trust Research & Innovation Department700
已完成
3 期
A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination gemcitabine and capecitabine therapy with concurent and sequential chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic pancreatic cancerocally advanced and metastatic pancreatic cancerLocally advanced and metastatic pancreatic cancerCancerISRCTN43482138The University of Liverpool (UK)1,062